| Company | Analyst |
|---|---|
| Cavendish | Mark Brewer |
| Peel Hunt | Dr Miles Dixon |
| Hardman & Co | Dr Martin Hall |
| Capital Network / Proactive Investors | Dr John Savin |
All of Cavendish, Hardman & Co and Capital Network’s research on their corporate clients are free to view via the following links:
Cavendish – There is a simple registration process for all non-institutional users and their corporate research is readily available
Capital Network/ Proactive Investors
Any opinions estimates or forecasts regarding the Company’s performance made by such analysts are theirs alone and do not represent opinions, forecasts or predictions of the Company or its Management. You should, therefore, not place undue reliance on the content of any such analyst report or statement.
Any reports issued may have become out of date following publication and should be read accordingly.
April 23, 2024
Edison Investment Research is terminating coverage on ABC Arbitrage (ABCA), paragon (PGN), Foresight Solar Fund (FSFL), Kendrion (KENDR), Lithium Power International (LPI), Triple Point Energy Transition (TENT), 4iG (4IG), e-therapeutics (...
January 11, 2024
Shield Therapeutics has appointed Santosh Shanbhag as chief financial officer (CFO) and member of the executive leadership team. Mr. Shanbhag was previously the CFO of Nasdaq-listed Akili, which he helped ...
December 8, 2023
Shield Therapeutics’ US commercialisation efforts continue to gather steam, with prescription volumes gearing up in Q323 (27,750 prescriptions, a 76% sequential growth over Q2 and higher than the combined H123 figure of 26,284) ...
September 29, 2023
Shield Therapeutics’ H123 results were largely as expected. Despite the minor operational adjustments with the commercialisation ramp-up, our long-term expectations remain unchanged. H123 revenue of $4.3m grew 65.8% y o y ...
May 4, 2023
Shield Therapeutics reported its FY22 preliminary results and Q123 business update, the key emphasis of which was the growing traction of Accrufer in the US following the December 2022 co-commercialisation deal ...
February 10, 2023
Shield Therapeutics’ FY22 trading update reported FY22 revenues of £8.5m, a material improvement on the £1.5m recorded in FY21 and broadly in line with our estimate of £8.8m. Sharp growth ...
December 16, 2022
Shield Therapeutics has announced a co-commercialisation deal for Accrufer in the US with Nasdaq-listed Viatris, which will involve an expanded salesforce and a 55%/45% revenue/cost split between the two companies. ...
September 8, 2022
Shield Therapeutics reported H122 results reflecting the fact that its commercial activities for Accrufer are bearing fruit. US total prescriptions soared fourfold to 11,223 compared to H221, including an 87% q-o-q increase ...
July 22, 2022
Shield Therapeutics’ (STX) value stems from Accrufer’s US market opportunity as the company seeks to maximise returns through self-commercialisation. Recent progress on payer coverage and prescription uplift bodes well ...
July 1, 2022
Shield Therapeutics reported FY21 results in line with market expectations, recording revenue of £1.5m, including a maiden £0.1m contribution from the United States after the July 2021 US launch of Accrufer. ...
August 23, 2021
Shield Therapeutics (STX) successfully launched its key asset, Accrufer (oral ferric maltol for iron deficiency), in the US market on 1 July, in line with previous guidance. The US commercialisation of ...
May 28, 2021
Shield Therapeutics (STX) has announced the appointment of a new chief executive officer (CEO), Greg Madison, with effect from 1 June 2021. Greg is a seasoned CEO with previous experience of the ...
May 4, 2021
Shield Therapeutics’ (STX) FY20 results reported total revenue of £10.4m reflecting an $11.4m (£9.7m) upfront payment received from ASK Pharm (Feraccru out-licensing deal that covers China) and £0.7m from royalties ...
March 5, 2021
Shield Therapeutics (STX) has placed c 83m shares at a deep discount (30.0p/share) to the market price, resulting in a gross raise of £25m. The funds will be utilised ...
February 1, 2021
Shield Therapeutics’ (STX’s) shares fell sharply in December 2020 on the announcement that a US partnering deal would not be completed in 2020 and that the company is considering launching Accrufer ...
December 11, 2020
Shield Therapeutics (STX) has announced it is broadening its strategy for commercialising Accrufer in the US (oral therapy for iron deficiency, approved by the FDA in July 2019) and no longer ...
September 18, 2020
Shield Therapeutics’ (STX’s) interim results highlight the progress made year to date. Re-analysis of the Feraccru/Accrufer AEGIS-H2H data show it is a credible alternative to IV iron ...
August 7, 2020
Shield Therapeutics (STX) has announced a technical update to findings from the AEGIS-H2H post-marketing study. The re-analysis demonstrates that Feraccru/Accrufer is a credible alternative to IV iron therapy ...
May 22, 2020
Shield Therapeutics (STX) has reported FY19 results; total revenue of £0.7m reflects royalties on Feraccru sales from European partner Norgine. 2019 achievements include FDA approval of STX’s key asset for ...
May 4, 2020
Shield Therapeutics (STX) has provided an updated trading statement ahead of FY19 results, expected at the end of May. In its January trading update, STX had guided to FY19 revenues ...
April 22, 2020
Shield Therapeutics (STX) has announced that founder Carl Sterritt has resigned from his role as CEO with mutual agreement from its main shareholders. Tim Watts has been appointed as CEO ...
March 18, 2020
Shield Therapeutics (STX) has announced a technical update to findings from the AEGIS-H2H post-marketing study, which evaluated Feraccru/Accrufer versus IV iron. The update does not affect any of ...
January 27, 2020
Today’s 2019 business and trading update highlights a landmark year for Shield Therapeutics. Feraccru/Accrufer (oral ferric maltol) is making inroads in Europe, with sales volumes growing 67% through commercialisation ...
January 13, 2020
Shield Therapeutics has kick-started 2020 by securing an out-licensing deal in China for its primary asset, Feraccru/Accrufer. The exclusive deal with China-based Beijing Aosaikang Pharmaceutical (ASK Pharm) covers China, Hong ...
August 8, 2019
Shield Therapeutics’ interim results highlight a momentous year to date, with the FDA approval of primary asset Feraccru/Accrufer, for the treatment of iron deficiency (ID) in adults with ...
July 26, 2019
Shield Therapeutics’ primary asset, Feraccru, has been approved by the FDA for the treatment of iron deficiency in patients with any underlying cause – the broadest possible label. It ...
July 9, 2019
Shield Therapeutics is a UK-based, speciality pharmaceutical company with a primary focus on commercialising its drug Feraccru, which is approved in Europe for the treatment of iron deficiency, with or ...
April 3, 2019
Shield Therapeutics reported FY18 results in line with our expectations. Total revenue of £11.9m included the £11.0m upfront payment from European partner Norgine. Operating expenses were substantially reduced ...
March 4, 2019
Shield Therapeutics has announced positive top-line data from a Phase IIIb study (AEGIS-H2H) for Feraccru, a CHMP-approved oral formulation of iron positioned for the treatment of iron deficiency (ID) ...
February 19, 2019
Shield Therapeutics is focused on the development and commercialisation of Feraccru, a CHMP-approved oral formulation of iron positioned for the treatment of iron deficiency (ID) with or without anaemia. In 2018, ...